MAIN CONTENT
A regulatory letter changes the market narrative
According to the South China Morning Post, Akeso stock was down as much as 31.8% on Monday morning. The violent move reflects expectations already built around ivonescimab, regarded as an important candidate in China’s innovative oncology pipeline. An intraday percentage should not be mistaken for a closing-price decline, nor should a stock-market reaction be confused with a clinical judgment about every potential use of the medicine.
On November 15, Summit Therapeutics announced receipt of a Complete Response Letter from the FDA concerning its biologics license application. Such a letter means the application cannot be approved as submitted. It is not a declaration that the molecule can never be developed, nor is it equivalent to banning further trials or permanently closing the door to a new submission supported by additional evidence.
Why two measures of success led to different conclusions
The application relied on the global phase 3 HARMONi study. It tested ivonescimab plus platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer whose disease had progressed after treatment with an EGFR-targeted tyrosine kinase inhibitor. These patients present a particularly difficult treatment challenge because targeted therapy may eventually stop controlling their disease.
















